ReviewJACC. Cardiovascular imaging2026
Understanding HFpEF Through Imaging: Strengths, Limitations, and Current State of the Art.
Review in JACC. Cardiovascular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome characterized by dyspnea caused by hemodynamic congestion, which develops at rest or with exercise. Noninvasive diagnosis remains challenging, because resting diastolic pressures may be normal, and even when abnormal, currently applied noninvasive indices lack sensitivity. The pathophysiology of HFpEF extends far beyond diastolic dysfunction, and such complexity can be better understood through imaging. This State-of-the-Art Review emphasizes echocardiography and other noninvasive imaging approaches as the first-line tools for HFpEF evaluation, while linking multimodality imaging to invasive hemodynamics as a physiologic reference standard. The authors emphasize evidence-based, multiparametric assessment, where combined cardiopulmonary exercise testing with exercise stress echocardiography can quantify the diverse reserve limitations that characterize HFpEF, including cardiac and extracardiac contributors, atrial and right heart dysfunction, pulmonary vascular and ventilatory limitation, dynamic atrioventricular regurgitation, extrinsic restraint, pulmonary congestion, and peripheral impairments, acknowledging that such phenotyping must be anchored to actionable findings and evidence-based interventions. The authors describe the potential role of exercise cardiac magnetic resonance and artificial intelligence-enabled imaging analysis for phenotyping and risk stratification. Finally, the authors propose an echo-first Bayesian pathway that updates pretest to posttest probability and supports identification of patients in whom invasive hemodynamic exercise testing may be required to confirm the diagnosis and validate imaging markers against invasively measured congestion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.